Moderna, Inc. (NASDAQ:MRNA) Director Sells $1,825,200.00 in Stock

Moderna, Inc. (NASDAQ:MRNA - Get Free Report) Director Noubar Afeyan sold 15,000 shares of Moderna stock in a transaction on Wednesday, May 8th. The shares were sold at an average price of $121.68, for a total transaction of $1,825,200.00. Following the completion of the sale, the director now owns 2,011,931 shares in the company, valued at approximately $244,811,764.08. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Noubar Afeyan also recently made the following trade(s):

• On Wednesday, May 1st, Noubar Afeyan sold 15,000 shares of Moderna stock. The shares were sold at an average price of $110.92, for a total transaction of $1,663,800.00.
• On Wednesday, April 24th, Noubar Afeyan sold 15,000 shares of Moderna stock. The shares were sold at an average price of $108.32, for a total transaction of $1,624,800.00.
• On Wednesday, April 17th, Noubar Afeyan sold 15,000 shares of Moderna stock. The shares were sold at an average price of $103.38, for a total transaction of $1,550,700.00.
• On Wednesday, April 10th, Noubar Afeyan sold 15,000 shares of Moderna stock. The shares were sold at an average price of $107.12, for a total transaction of $1,606,800.00.
• On Wednesday, April 3rd, Noubar Afeyan sold 15,000 shares of Moderna stock. The shares were sold at an average price of $101.68, for a total transaction of $1,525,200.00.
• On Wednesday, March 27th, Noubar Afeyan sold 15,000 shares of Moderna stock. The stock was sold at an average price of $109.06, for a total value of $1,635,900.00.
• On Wednesday, March 20th, Noubar Afeyan sold 15,000 shares of Moderna stock. The stock was sold at an average price of $102.39, for a total value of $1,535,850.00.
• On Wednesday, March 13th, Noubar Afeyan sold 15,000 shares of Moderna stock. The stock was sold at an average price of $108.54, for a total value of $1,628,100.00.

Moderna Stock Performance

Moderna stock traded down $5.38 during midday trading on Friday, hitting $117.31. The stock had a trading volume of 4,221,062 shares, compared to its average volume of 4,103,396. The firm's fifty day moving average is $107.20 and its two-hundred day moving average is $95.43. The company has a market capitalization of $44.96 billion, a PE ratio of -7.83 and a beta of 1.57. Moderna, Inc. has a 52-week low of $62.55 and a 52-week high of $142.79. The company has a current ratio of 4.03, a quick ratio of 3.91 and a debt-to-equity ratio of 0.04.

Moderna (NASDAQ:MRNA - Get Free Report) last released its earnings results on Thursday, May 2nd. The company reported ($3.07) earnings per share (EPS) for the quarter, topping the consensus estimate of ($3.59) by $0.52. Moderna had a negative net margin of 115.82% and a negative return on equity of 20.10%. The company had revenue of $167.00 million during the quarter, compared to analyst estimates of $93.26 million. During the same period in the prior year, the firm posted $0.19 EPS. The firm's quarterly revenue was down 91.0% compared to the same quarter last year. On average, research analysts forecast that Moderna, Inc. will post -7.47 EPS for the current year.

Institutional Investors Weigh In On Moderna

A number of institutional investors have recently added to or reduced their stakes in the stock. International Assets Investment Management LLC grew its holdings in shares of Moderna by 6,528.9% in the fourth quarter. International Assets Investment Management LLC now owns 387,656 shares of the company's stock valued at $38,552,000 after purchasing an additional 381,808 shares in the last quarter. abrdn plc grew its holdings in shares of Moderna by 477.5% in the fourth quarter. abrdn plc now owns 483,574 shares of the company's stock valued at $48,091,000 after purchasing an additional 399,843 shares in the last quarter. Van ECK Associates Corp grew its holdings in shares of Moderna by 19.2% in the fourth quarter. Van ECK Associates Corp now owns 270,774 shares of the company's stock valued at $26,929,000 after purchasing an additional 43,646 shares in the last quarter. Invesco Ltd. grew its holdings in shares of Moderna by 19.8% in the third quarter. Invesco Ltd. now owns 3,126,028 shares of the company's stock valued at $322,887,000 after purchasing an additional 517,683 shares in the last quarter. Finally, First Trust Direct Indexing L.P. purchased a new position in shares of Moderna in the fourth quarter valued at $372,000. 75.33% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research firms have recently issued reports on MRNA. Oppenheimer lifted their price target on Moderna from $142.00 to $163.00 and gave the stock an "outperform" rating in a research report on Friday, May 3rd. Canaccord Genuity Group lifted their price target on Moderna from $91.00 to $106.00 and gave the stock a "hold" rating in a research report on Friday, May 3rd. Jefferies Financial Group reissued a "buy" rating and issued a $125.00 target price on shares of Moderna in a research report on Tuesday, April 9th. William Blair reissued a "market perform" rating on shares of Moderna in a research report on Monday, April 1st. Finally, UBS Group boosted their target price on Moderna from $143.00 to $151.00 and gave the stock a "buy" rating in a research report on Tuesday. Two analysts have rated the stock with a sell rating, eight have issued a hold rating and six have issued a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Hold" and an average price target of $126.89.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.